Ton Logtenberg is the founder and former President and CEO of Merus N.V., a Nasdaq listed clinical-stage biotechnology company advancing leading-edge, targeted treatments for cancer patients based on multi-specific antibodies. Ton is the also the founder and CEO of U-BiSys, a Dutch biotechnology company that merged with Introgene to become Crucell, where he served as the Chief Scientific Officer responsible for the discovery and development of vaccines and antibodies. Together with dr. Hans Clevers, Ton founded the HUB foundation for organoid technology and served on the board of directors and supervisory board. Ton is currently an Operational Partner at Forbion Capital Partners and Chairman of the Board of UK-based biotech company Mestag Therapeutics. Together with Paul Parren, he recently founded three start-up companies based in Utrecht, The Netherlands, Gyes B.V., Moirea B.V., and Olethros B.V., that pioneer innovative, multifunctional antibody-based approaches in immune-oncology and inflammatory and autoimmune diseases. Ton received a Ph.D. in immunology from Utrecht University and did his post-doctoral work at Columbia University with Dr. Frederique Alt. Ton was a professor of Immuno-biotechnology at Utrecht University and is currently professor in Entrepreneurship in the Life Sciences at the same University.